When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AZN - Syndax's Latest Data Disappoints But The True Value Lies With SNDX-5613 And SNDX-6352
AstraZeneca PLC
Syndax Pharmaceuticals (SNDX) had recently failed a phase 3 study using its drug entinostat plus exemestane, to treat patients with advanced HR+/HER2- breast cancer who had progressed on a non-steroidal aromatase inhibitor. This study failed to meet the primary endpoint of overall survival and thus the drug can't be advanced for this indication. While this is a huge blow to the company, I believe there is more value with an earlier stage drug known as SNDX-5613. This drug recently showed positive results in a phase 1 study in several patients. If this drug